S 64315

Drug Profile

S 64315

Alternative Names: MIK 665; S64315

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Servier; Vernalis
  • Developer Novartis; Servier; Vernalis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes

Most Recent Events

  • 12 Jul 2017 Phase-I clinical trials in Lymphoma (Second-line therapy or greater) in Spain, Japan (IV) (NCT02992483)
  • 12 Jul 2017 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in Spain, Japan (IV) (NCT02992483)
  • 15 Mar 2017 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in Australia (IV) (NCT02979366)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top